iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
about
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Autoimmunity and tumor immunology: two facets of a probabilistic immune systemPrognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancerMetabolic system alterations in pancreatic cancer patient serum: potential for early detection.Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma PathophysiologyPancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models.Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.Biomarkers for early diagnosis of pancreatic cancer.Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.Complement in Pancreatic Disease-Perpetrator or Savior?Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma.Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling.Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
P2860
Q33655712-10FE42C4-C367-4E77-AB3C-9F5093693BD9Q34537272-ED6F26C7-1404-4E3A-9ABA-0B7CE94FB2B5Q34669394-9955ADBE-0FCD-44D0-A4B1-56195248D933Q34984999-9B6CB3EC-61BE-4F66-BE83-F4D02941DE4CQ35101910-61481835-2923-4F38-85E0-3233D507DB9EQ35903573-1E7EB7F5-F2F3-469F-B9D5-E748DFB80E13Q36443870-00218A0B-678C-4B5A-B9E6-58446FEAC7C5Q36763283-673D5DA7-768F-4D62-AA60-F563DF62D969Q37714287-057FD18D-3F2A-4F2D-9C3E-7F54B01DAEF9Q38265405-AEDB12F3-040B-41E6-ADFD-44714C985D7DQ38777938-E9493D77-9533-4651-BECA-C7032DAE8EE2Q38816181-DBFCCB66-65E2-42F3-927A-B189136F10EEQ38988021-700B5855-533C-4DD4-BD08-DC7AD3A8A71DQ41645489-2322F7CE-1593-4B24-A81D-ED57C8F1D44FQ41851428-EB21EEF3-3B2A-4A94-AB36-E05B80D37EF8Q47418676-B735AC64-B404-489E-BDDB-4B763AC89C50Q47421750-6FC38985-CDDD-4C94-894B-B3F63BEA4DE5Q52595056-C829D99E-A4B4-40B3-A8D1-13BE5B67172EQ53247758-69E38B7A-C6F6-4A7E-8D2F-F41B6032F234
P2860
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
iTRAQ reveals candidate pancre ...... jaundice on their performance.
@en
type
label
iTRAQ reveals candidate pancre ...... jaundice on their performance.
@en
prefLabel
iTRAQ reveals candidate pancre ...... jaundice on their performance.
@en
P2093
P2860
P356
P1476
iTRAQ reveals candidate pancre ...... jaundice on their performance.
@en
P2093
C Jenkinson
C W Michalski
J P Neoptolemos
N R Kitteringham
R E Jenkins
W Greenhalf
P2860
P2888
P304
P356
10.1038/BJC.2013.150
P407
P577
2013-04-11T00:00:00Z